Ongoing Clinical Trials for NF-Related Issues

 

The following clinical trials and other NF-related trials can be found at ClinicalTrials.gov by searching “neurofibromatosis”. While some of the information is very technical, the basic information on the purpose of the trial is usually straightforward. There is detailed information on who is eligible and at what locations the trial is open.

 

-Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

 

The connection between neurofibromatosis, tumors, and cancer treatment is strong, and this has made clinical trials for NF-related tumors a major part of ongoing research in NF. New medications that block the growth of cells that lack the NF1 protein or the NF2 protein have been discovered and are useful in some cancers that are not part of NF. There is a particularly promising set of medications that are being tested for progressive plexiform neurofibromas of NF1. Dr. Brigitte Widemann at the National Cancer Institute and collaborators at many NF Clinics are currently testing “MEK inhibitors” for progressing plexiform neurofibromas.  

 

-Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain

 

Clinical trials that address other features of NF are also very important. This trial, sponsored by the National Cancer Institute, is a good example that involves dealing with pain management for NF patients with tumors. 

Tags:

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Dear Friends of NF Tennessee,

We hope you are having a great Summer. Fall 2018 – Spring 2019 has been an exciting time for the local NF community and f...

Blog Post #2

August 25, 2019

1/5
Please reload

Recent Posts

August 25, 2019

July 1, 2018

January 27, 2017

January 27, 2017

Please reload

Archive
Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square